N. Roche (Paris, France), E. Tufvesson (Lund, Sweden)
Subcutaneous specific immunotherapy (SCIT) added to omalizumab in severe allergic asthma patients -efficacy and safety M.Christopoulou, J.Moisidis, L.Panteli and A.Christopoulos Asthma Clinics Private outpatient clinic Patras/Greece
A. Christopoulos (Patras, Greece), M. Christopoulou (Patras, Greece), L. Panteli (Patras, Greece), I. Moisidis (Patras, Greece), I. Christopoulos (Patras, Greece)
|   |
Improvement of health-related quality of life after 3 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany
C. Gessner (Leipzig, Germany), B. Akyildiz (Hamburg, Germany), M. Martini (Hamburg, Germany), T. Meyer-Duderstaedt (Hamburg, Germany), R. Koczulla (Marburg, Germany)
| |
Effectiveness of initiating biologics in severe asthma patients with high steroid exposure
W. Chen (Singapore , Singapore), T. N Tran (Gaithersburg, United States), M. Sadatsafavi (Vancouver, Canada), E. Garcia Gil (Barcelona, Spain), M. Alacqua (Milan, Italy), A. Menzies Gow (London, United Kingdom), L. G Heaney (Belfast, United Kingdom), P. E.Pfeffer (London, United Kingdom), J. Maspero (Buenos Aires , Argentina), M. Peters (Sydney, Australia), G. C Christoff (Sofia , Bulgaria), M. Bhutani (Alberta, Canada), C. A.Torres-Duque (Bogotá, Colombia), C. Ulrik (Hvidovre, Denmark), A. Altraja (Tartu , Estonia), L. Lehtimaki (Tampere, Finland), C. Taille (Paris, France), A. I.Papaioannou (Athens, Greece), S. Salvi (Pune, India), R. W Costello (Dublin, Ireland), G. Walter Canonica (Milan , Italy), T. Iwanaga (Osakasayama, Japan), M. Al-Ahmad (Kuwait , Kuwait), D. Larenas-Linnemann (Ciudad de México, Mexico), P. Kuna (Lódz, Poland), J. A.Fonseca (Porto, Portugal), R. Al-Lehebi (Riyadh, Saudi Arabia), M. Koh Siyue (Singapore, Singapore), C. Rhee (Seoul, Republic of Korea), L. Perez-De-Llano (Lugo, Spain), R. C Jones (Plymouth, United Kingdom), D. Perng (Taipei, Taiwan), E. Wang (Denver, United States), F. Hoyte (Denver, United States), N. Wong Chong Boon (Singapore , Singapore), J. Lyu (Singapore , Singapore), C. Ariti (Singapore , Singapore), R. Murray (Singapore , Singapore), C. Goh (Singapore , Singapore), I. Joshi (Singapore , Singapore), N. Eleangovan (Singapore , Singapore), D. Price (Singapore , Singapore)
| |
Complex therapy in patients with bronchial asthma on the background of gastroesophageal reflux disease (GERD)
I. Koretskaia (Dnepropetrovsk, Ukraine), Y. Dytyatkovska (Dnepropetrovsk, Ukraine), N. Nedogibchenko (Dnepropetrovsk, Ukraine), A. Yevtushenko (Dnepropetrovsk, Ukraine), K. Gashynova (Dnipro, Ukraine)
| |
Adolescence to early adulthood transition in French severe asthmatic children treated with omalizumab
C. Taillé (Paris, France), M. Humbert (Le Kremlin-Bicêtre, France), A. Bourdin (Montpellier, France), R. Niarra (Rueil Malmaison, France), C. Thonnelier (Rueil Malmaison, France), A. Lajoinie (Lyon, France), A. Rigault (Lyon, France), M. Molimard (Bordeaux, France), A. Deschildre (Lille, France)
| |
Specialist care among adults with asthma and frequent use of oral corticosteroids – a nationwide Danish register-study
I. Skov (Odense, Denmark), H. Madsen (Odense, Denmark), J. Andersen (Odense, Denmark), A. Pottegård (Odense, Denmark), J. Davidsen (Odense, Denmark)
| |
Outcomes from treating rhinitis in patients with refractory breathlessness
R. Daly (Manchester, United Kingdom), S. Ludlow (Manchester, United Kingdom), T. Pantin (Manchester, United Kingdom), S. Fowler (Manchester, United Kingdom)
| |
Real-life comparative study on the effectiveness of benralizumab, mepolizumab and omalizumab in severe allergic asthma associated with nasal polyps
A. TIOTIU (Nancy, France), P. Mendez-Brea (Santiago de Compostela, Spain), I. Ioan (Nancy, France), R. Romero-Fernandez (Santiago de Compostela, Spain), J. Oster (Colmar, France), T. Hoang (Colmar, France), P. Roux (Besançon, France), D. Ochoa-Gutierrez (Strasbourg, France), P. Bonniaud (Dijon, France), F. De Blay (Strasbourg, France), F. Gonzalez-Barcala (Santiago de Compostela, Spain)
| |
Prevalence of anxiety and depression in patients with severe Asthma who are receiving biologic therapy.
J. Watson (London, United Kingdom), C. Peach (London, United Kingdom), N. Price (London, United Kingdom), J. Evans (London, United Kingdom), A. Draper (London, United Kingdom), S. Ruickbie (London, United Kingdom)
| |
Suppressive effect of corticosteroid treatment on urinary levels of androgens and cortisol in mild and severe asthma
V. Yasinska (Stockholm, Sweden), C. Gómez (Stockholm, Sweden), J. Kolmert (Stockholm, Sweden), A. James (Stockholm, Sweden), L. Andersson (Stockholm, Sweden), B. Dahlén (Stockholm, Sweden), C. Wheelock (Stockholm, Sweden), S. Dahlén (Stockholm, Sweden), E. Wikström-Jonsson (Stockholm, Sweden), (. On Behalf Of The U-Biopred Study Group) (Stockholm, Sweden)
| |
Economic impact of oral corticosteroids in severe asthmatics: a simulation study in selected European countries
A. Bourdin (Montpellier, France), E. Bel (Amstersam, Netherlands), B. Dahlén (Stockholm, Sweden), R. Djukanovic (Southampton, United Kingdom), E. Heffler (Milano, Italy), P. Kuna (Lodz, Poland), R. Louis (Liege, Belgium), C. Porsbjerg (Copenhagen, Denmark), D. Ramos-Barbon (Barcelona, Spain), S. Škrgat (Ljubljana, Slovenia), G. Bruno (Pavia, Italy), S. Di Matteo (Milano, Italy), C. Martinotti (Milano, Italy), G. Colombo (Pavia, Italy), T. Paulsson (London, United Kingdom), B. Mascialino (Verona, Italy)
| |
Assessing variation in severe asthma care in England: a national benchmarking study
J. Rose (Oxford , United Kingdom), S. Gadhia (Oxford , United Kingdom), M. Lepetyukh (Oxford , United Kingdom), B. Williams (Sussex, United Kingdom), H. Rupani (Southampton, United Kingdom), G. D'Ancona (London, United Kingdom)
| |
Using clusters of asthmatic patients to quantitatively estimate, prior to initiating treatment, the likelihood of ß2-agonist response in asthma patients
E. Delgado-Eckert (Basel, Switzerland), C. Thamrin (Sydney, Australia), I. Town (Wellington, New Zealand), D. Taylor (Edinburgh, United Kingdom), U. Frey (Basel, Switzerland)
| |
Clinical Characteristics and Disease Burden of Severe Asthma According to Oral Corticosteroid Dependence: Real-World Assessment from the Korean Severe Asthma Registry (KoSAR)
J. Lee (Seoul, Republic of Korea), H. Kim (Busan, Republic of Korea), C. Park (Busan, Republic of Korea), S. Park (Seoul, Republic of Korea), S. Park (Seoul, Republic of Korea), H. Lee (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea)
| |
Prevalence of asthma-COPD overlap in COPD and severe asthma cohorts
H. Joo (Seoul, Republic of Korea), S. Park (Seoul, Republic of Korea), S. Park (Seoul, Republic of Korea), S. Park (Seoul, Republic of Korea), S. Kim (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea), K. Yoo (Seoul, Republic of Korea), K. Jung (Anyang, Republic of Korea), C. Rhee (Seoul, Republic of Korea)
| |
Adherence to inhalers and asthma control assessed by two validated self-reported questionnaires.
S. Novakova (Plovdiv, Bulgaria), P. Novakova (Sofia, Bulgaria)
| |
Impact of baseline characteristics on clinical remission achievement in severe asthma
C. Domingo Ribas (Barcelona, Spain), I. Pavord (Oxford, United Kingdom), D. Bañas Conejero (Madrid, Spain), R. Price (Stevenage, Hertfordshire, United Kingdom), A. Pullan (Knutsford, Cheshire, United Kingdom), J. Oppenheimer (Newark, NJ, United States), L. Heaney (Belfast, United Kingdom), H. Nagase (Tokyo, Japan), E. Pizzichini (Santa Catarina, Brazil; and Brentford, Middlesex, United Kingdom), P. Howarth (Brentford, Middlesex, United Kingdom), F. Gardiner (Brentford, Middlesex, United Kingdom)
| |
Innovation in drug development: applying human factors to understand asthmatic patients’ needs.
M. Lombardini (Parma, Italy), G. Marenghi (Parma, Italy), F. Bianchi (Parma, Italy)
| |
Analysis of the tolerance and safety of inhaled antibiotics and hypertonic saline solution in patients with bronchial hyperreactivity
A. Perez Figuera (Madrid, Spain), R. Nieto Royo (Madrid, Spain), R. Morillo Guerrero (Madrid, Spain), C. Almonacid Sánchez (Toledo, Spain), A. Solier López (Madrid, Spain), E. Barbero Herranz (Madrid, Spain), D. Durán Barata (Madrid, Spain), B. Pintado Cort (Madrid, Spain), D. Velasco Álvarez (Madrid, Spain), L. Máiz Carro (Madrid, Spain)
| |
Comorbidities in severe and non-severe asthma: a nationwide population-based observational study
H. Kankaanranta (Tampere, Finland), A. Viinanen (Turku, Finland), P. Ilmarinen (Espoo, Finland), J. Mehtälä (Helsinki, Finland), T. Ylisaukko-Oja (Helsinki, Finland), J. Idänpään-Heikkilä (Espoo, Finland), L. Lehtimäki (Tampere, Finland)
| |